A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

NCT02076412 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

74

Enrollment

INDUSTRY

Sponsor class

Conditions

Immune Thrombocytopenic Purpura

Interventions

DRUG: Fostamatinib Disodium
DRUG: Placebo

Sponsor

Rigel Pharmaceuticals